Geron's Greenwood steps aside as CEO for Scarlett
This article was originally published in Clinica
US stem cell specialist Geron has made John Scarlett CEO and appointed him to the board of directors, replacing David Greenwood, who has served as interim CEO, president and CFO since February. Mr Greenwood will retain his roles as president and CFO, but has also resigned from Geron's board in connection with the transition. Mr Scarlett was most recently president and CEO of Proteolix, a biotech acquired by Onyx Pharmaceuticals in 2009.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.